Journal: BMC Cancer

Article Title: Synergistic apoptosis induction in myelodysplastic syndrome cells by azacitidine and PIM-2 inhibitors via nuclear factor-kappa B pathway inhibition

doi: 10.1186/s12885-025-14657-0

Figure Lengend Snippet: Synergistic inhibition of proliferation of MDS cells by azacitidine and SMI-16a. a The IC 50 values of azacitidine and SMI-16a against MDS cells were determined to be 20 nM and 25 µM, respectively. b Combination therapy with azacitidine and SMI-16a significantly suppressed cell proliferation compared to monotherapy. c Combination effects were evaluated using the CalcuSyn software, with combination index (CI) < 1 indicating synergy, CI = 1 indicating additivity, and CI > 1 indicating antagonism

Article Snippet: Azacitidine and SMI-16a (a PIM-2 inhibitor) were supplied by MedChemExpress (Monmouth Junction, NJ, USA) and stored as stock solutions at − 80 °C.

Techniques: Inhibition, Software

Journal: BMC Cancer

Article Title: Synergistic apoptosis induction in myelodysplastic syndrome cells by azacitidine and PIM-2 inhibitors via nuclear factor-kappa B pathway inhibition

doi: 10.1186/s12885-025-14657-0

Figure Lengend Snippet: Combination of azacitidine and SMI-16a induces cell apoptosis. A Apoptosis was assessed using propidium iodide (PI) and annexin V staining followed by flow cytometry after 48 h of treatment. B TUNEL assay results for MDS cell lines, including quantitative analysis of TUNEL-positive cells. C Western blot analysis showing upregulation of the apoptosis-associated proteins PARP and cleaved caspase-3. * indicates a significant difference compared with the control ( P < 0.05) and ** indicates a significant difference compared with monotherapy ( P < 0.05)

Article Snippet: Azacitidine and SMI-16a (a PIM-2 inhibitor) were supplied by MedChemExpress (Monmouth Junction, NJ, USA) and stored as stock solutions at − 80 °C.

Techniques: Staining, Flow Cytometry, TUNEL Assay, Western Blot, Control

Journal: BMC Cancer

Article Title: Synergistic apoptosis induction in myelodysplastic syndrome cells by azacitidine and PIM-2 inhibitors via nuclear factor-kappa B pathway inhibition

doi: 10.1186/s12885-025-14657-0

Figure Lengend Snippet: Inhibition of NF-κB pathway-related protein expression by azacitidine and SMI-16a. a Western blot analysis demonstrating downregulation of phosphorylated p65 (p-p65) and phosphorylated IκB (p-IκB) expression. b Western blot analysis showing downregulation of survivin and Bcl-2 expression

Article Snippet: Azacitidine and SMI-16a (a PIM-2 inhibitor) were supplied by MedChemExpress (Monmouth Junction, NJ, USA) and stored as stock solutions at − 80 °C.

Techniques: Inhibition, Expressing, Western Blot

Journal: BMC Cancer

Article Title: Synergistic apoptosis induction in myelodysplastic syndrome cells by azacitidine and PIM-2 inhibitors via nuclear factor-kappa B pathway inhibition

doi: 10.1186/s12885-025-14657-0

Figure Lengend Snippet: Azacitidine and SMI-16a induce apoptosis in primary CD34 + cells. a Schematic diagram of drug treatment of primary CD34 + cells. The illustration was created with BioRender.com. b Induction of apoptosis in primary CD34 + cells by azacitidine and SMI-16a. Primary CD34 + cells obtained from patients with high-risk MDS and AML were treated with azacitidine and SMI-16a for 24 h. The combination of these two drugs induced apoptosis in CD34 + cells

Article Snippet: Azacitidine and SMI-16a (a PIM-2 inhibitor) were supplied by MedChemExpress (Monmouth Junction, NJ, USA) and stored as stock solutions at − 80 °C.

Techniques:

Journal: Cancers

Article Title: Computed Tomography-Based Sarcopenia and Pancreatic Cancer Survival—A Comprehensive Meta-Analysis Exploring the Influence of Definition Criteria, Prevalence, and Treatment Intention

doi: 10.3390/cancers17040607

Figure Lengend Snippet: Main characteristics of the studies included in this meta-analysis. ASM, appendicular skeletal muscle. F, female. M, male. m (IQR), median (interquartile range). NOS, Newcastle–Ottawa scale. PC, pancreatic cancer. PDAC, pancreatic ductal adenocarcinoma. PMI, psoas muscle mass index. SMI, skeletal muscle mass index. TPV, total psoas volume. TSM, total skeletal muscle index. X + SD, mean + standard deviation. * From data calculation provided in the methodology of the article, the corresponding values for class I sarcopenia are 57.5 cm 2 /m 2 and 38.3 cm 2 /m 2 for men and women, respectively. Further details can be consulted in [ 24 ].

Article Snippet: Hiroyuki Asama et al. (2022) [ ] , 124 , 69 (40–84) , 45.9 , 50.8 , SMI , Nishikawa et al. [ ] , M < 42 cm 2 /m 2 F < 38 cm 2 /m 2 , Unresectable PDAC , Palliative.

Techniques: Standard Deviation, Imaging